Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
暂无分享，去创建一个
U. Goldbourt | S. Behar | E. Kaplinsky | H. Reicher-Reiss | J. Agmon | A. Marmor | B. Rabinowitz | M. Zion | A. Caspi | L. Mandelzweig | E. Graff | Y. Kishon | Y. Friedman | J. Weisbort | M. Flich | S. Sclarovsky, | Abraham Palant | Jacob Agmon | U. Goldbourt | E. Graft | Yehezkiel Kishon | A. Caspi | Edward Abinader | Leon Aharon | Shimeon Braun | Daniel David | Natalio Kristal | Noa Leil | Walter Markiewicz | Benjamin Pelled | Leornardo Reisin | Nathan Roguin | Tiberio Rosenfeld | Zwi Schlesinger | Libi Sherf | Daniel Tzivoni | Izhar Zahavi | Daniel Brunner | E. Abinader